FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2223110203> ?p ?o ?g. }

• W2223110203 abstract "Background: Thyroid hormones, regulators of metabolism and development in healthy tissue, stimulate tumor growth in vitro and are associated with breast cancer risk. We investigated the effect of chemotherapy on thyroid function and the extent to which it can predict the pathological response in patients with HER2 negative stage II/III breast cancer taking part in the NEOZOTAC phase III trial, randomizing between 6 cycles of neoadjuvant TAC chemotherapy with or without additional zoledronic acid. Moreover, we examined the impact of thyroid function on chemotherapy toxicity. Methods: Serum samples of 38 of the 105 patients who participated in the side study of the NEOZOTAC trial were available for analyses. Serum free thyroxin (fT4) and thyroid stimulating hormone (TSH) levels were measured at baseline and compared with fT4 and TSH levels before the 2 nd and 6 th chemotherapy cycle. FT4 and TSH levels were also compared between subjects with and without pathological complete response (pCR). The relation between toxicity, per side effect of any CTC grade, and the variation in fT4 and TSH levels during chemotherapy was tested. Results: Serum samples at baseline, before the 2 nd chemotherapy cycle and at end of treatment were available for 31, 30 and 21 patients, respectively. In the total population, the mean baseline fT4 level was 16,0pmol/L and the mean TSH level 1,11mU/L. There were no differences between subjects solely treated with TAC chemotherapy and subjects treated with zoledronic acid as an adjunct to TAC with respect to the mean fT4 and TSH at each time point. Baseline TSH levels tended to be higher in patients who achieved pCR ( p =0.035 univariate analysis and p=0.074 multivariate analysis) (Table 1). During 6 cycles of chemotherapy, fT4 levels decreased ( p p =0.019). Interestingly, the decrease of fT4 was significantly greater in patients without nausea, vomiting or sensory neuropathy, than in patients with those side effects (p=0.037, p=0.043 and p=0.050 respectively). Conclusion: TSH levels at baseline were higher in breast cancer patients with pCR. Chemotherapy blunts thyroid function, and a large decline of fT4 was associated with less side effects. These data suggest that thyroid hormones may interact with chemotherapy to modulate treatment (side-) effects in patients with breast cancer. Citation Format: S de Groot, A Charehbili, L GM Janssen, E M Dijkgraaf, V THBM Smit, L W Kessels, A van Bochove, H WM van Laarhoven, E Meershoek-Klein Kranenbarg, A E van Leeuwen-Stok, G J Liefers, C JH van de Velde, J WR Nortier, J JM van der Hoeven, H Pijl, J R Kroep. Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-06-50." @default.
• W2223110203 created "2016-06-24" @default.
• W2223110203 creator A5009256388 @default.
• W2223110203 creator A5010512189 @default.
• W2223110203 creator A5015398820 @default.
• W2223110203 creator A5016939168 @default.
• W2223110203 creator A5023493169 @default.
• W2223110203 creator A5031668702 @default.
• W2223110203 creator A5031880856 @default.
• W2223110203 creator A5042579611 @default.
• W2223110203 creator A5048152930 @default.
• W2223110203 creator A5054942006 @default.
• W2223110203 creator A5057190473 @default.
• W2223110203 creator A5059199132 @default.
• W2223110203 creator A5059606948 @default.
• W2223110203 creator A5070946938 @default.
• W2223110203 creator A5087082570 @default.
• W2223110203 creator A5091322627 @default.
• W2223110203 date "2015-04-30" @default.
• W2223110203 modified "2023-09-27" @default.
• W2223110203 title "Abstract P3-06-50: Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)" @default.
• W2223110203 doi "https://doi.org/10.1158/1538-7445.sabcs14-p3-06-50" @default.
• W2223110203 hasPublicationYear "2015" @default.
• W2223110203 type Work @default.
• W2223110203 sameAs 2223110203 @default.
• W2223110203 citedByCount "0" @default.
• W2223110203 crossrefType "proceedings-article" @default.
• W2223110203 hasAuthorship W2223110203A5009256388 @default.
• W2223110203 hasAuthorship W2223110203A5010512189 @default.
• W2223110203 hasAuthorship W2223110203A5015398820 @default.
• W2223110203 hasAuthorship W2223110203A5016939168 @default.
• W2223110203 hasAuthorship W2223110203A5023493169 @default.
• W2223110203 hasAuthorship W2223110203A5031668702 @default.
• W2223110203 hasAuthorship W2223110203A5031880856 @default.
• W2223110203 hasAuthorship W2223110203A5042579611 @default.
• W2223110203 hasAuthorship W2223110203A5048152930 @default.
• W2223110203 hasAuthorship W2223110203A5054942006 @default.
• W2223110203 hasAuthorship W2223110203A5057190473 @default.
• W2223110203 hasAuthorship W2223110203A5059199132 @default.
• W2223110203 hasAuthorship W2223110203A5059606948 @default.
• W2223110203 hasAuthorship W2223110203A5070946938 @default.
• W2223110203 hasAuthorship W2223110203A5087082570 @default.
• W2223110203 hasAuthorship W2223110203A5091322627 @default.
• W2223110203 hasConcept C121608353 @default.
• W2223110203 hasConcept C126322002 @default.
• W2223110203 hasConcept C134018914 @default.
• W2223110203 hasConcept C143998085 @default.
• W2223110203 hasConcept C2776326535 @default.
• W2223110203 hasConcept C2776694085 @default.
• W2223110203 hasConcept C2779761222 @default.
• W2223110203 hasConcept C2908647359 @default.
• W2223110203 hasConcept C2993291352 @default.
• W2223110203 hasConcept C526584372 @default.
• W2223110203 hasConcept C530470458 @default.
• W2223110203 hasConcept C71315377 @default.
• W2223110203 hasConcept C71924100 @default.
• W2223110203 hasConcept C90924648 @default.
• W2223110203 hasConcept C99454951 @default.
• W2223110203 hasConceptScore W2223110203C121608353 @default.
• W2223110203 hasConceptScore W2223110203C126322002 @default.
• W2223110203 hasConceptScore W2223110203C134018914 @default.
• W2223110203 hasConceptScore W2223110203C143998085 @default.
• W2223110203 hasConceptScore W2223110203C2776326535 @default.
• W2223110203 hasConceptScore W2223110203C2776694085 @default.
• W2223110203 hasConceptScore W2223110203C2779761222 @default.
• W2223110203 hasConceptScore W2223110203C2908647359 @default.
• W2223110203 hasConceptScore W2223110203C2993291352 @default.
• W2223110203 hasConceptScore W2223110203C526584372 @default.
• W2223110203 hasConceptScore W2223110203C530470458 @default.
• W2223110203 hasConceptScore W2223110203C71315377 @default.
• W2223110203 hasConceptScore W2223110203C71924100 @default.
• W2223110203 hasConceptScore W2223110203C90924648 @default.
• W2223110203 hasConceptScore W2223110203C99454951 @default.
• W2223110203 hasLocation W22231102031 @default.
• W2223110203 hasOpenAccess W2223110203 @default.
• W2223110203 hasPrimaryLocation W22231102031 @default.
• W2223110203 hasRelatedWork W1990780967 @default.
• W2223110203 hasRelatedWork W1993586172 @default.
• W2223110203 hasRelatedWork W2027307359 @default.
• W2223110203 hasRelatedWork W2085738216 @default.
• W2223110203 hasRelatedWork W2229067056 @default.
• W2223110203 hasRelatedWork W2314610986 @default.
• W2223110203 hasRelatedWork W2328409282 @default.
• W2223110203 hasRelatedWork W23594430 @default.
• W2223110203 hasRelatedWork W2362623036 @default.
• W2223110203 hasRelatedWork W2487498391 @default.
• W2223110203 hasRelatedWork W2591926557 @default.
• W2223110203 hasRelatedWork W2592707283 @default.
• W2223110203 hasRelatedWork W2594789914 @default.
• W2223110203 hasRelatedWork W2967560936 @default.
• W2223110203 hasRelatedWork W2996231784 @default.
• W2223110203 hasRelatedWork W3004099594 @default.
• W2223110203 hasRelatedWork W3010529280 @default.
• W2223110203 hasRelatedWork W3013368393 @default.
• W2223110203 hasRelatedWork W3032730990 @default.
• W2223110203 hasRelatedWork W3032762942 @default.
• W2223110203 isParatext "false" @default.
• W2223110203 isRetracted "false" @default.
• W2223110203 magId "2223110203" @default.
• W2223110203 workType "article" @default.